-
Investornewsbreaks Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Promotes Siobhan Fogarty To Chief Technical Officer
04 Feb 2025 22:08 GMT
… roles at Elan Corporation, GlaxoSmithKline, Fuisz Technologies and Biovail … #39;s newsroom at
About InvestorWire
InvestorWire (“IW”) is a specialized … 7000 Office
[email protected]
InvestorWire is powered by IBN
MENAFN04022025000224011066ID1109167834
-
StockWatch: Up-to-$500B AI Venture Sparks Investor Interest, and Questions
24 Jan 2025 19:57 GMT
Investors flocked this past week to … (NASDAQ: MSFT) OpenAI’s largest investor with a 49% stake translating … agreed to oversee its operations.
Investors reacted to the Stargate news … (LSE: AZN), CSL (ASX: CSL), GlaxoSmithKline (LSE and NYSE: GSK), Novavax …
-
Bio factory demand slumps as investor cash dries up. What does the future in Philly look like?
20 Jan 2025 14:50 GMT
… facilities amid the flood of investor cash that boosted start-up … to fruition,” Kelly says.
Big investors have cut back on funding … have pulled back. He noted GlaxoSmithKline’s plans for an up …
-
Pharma stocks: Biocon up 3.84% on US FDA nod for Malaysia unit; Divi’s Lab gains 0.61%, Mankind Pharma slips 3.75%, GlaxoSmithKline drops 2.42%
13 Jan 2025 06:03 GMT
… from the US FDA, boosting investor sentiment.
Divi’s Laboratories also … ₹2,637.10, followed by GlaxoSmithKline Pharmaceuticals and Aurobindo Pharma, which … : ₹2,637.10 (-3.75%)
GlaxoSmithKline Pharmaceuticals: ₹2,137.50 (-2 …
-
Equities market: Why investor fears persist despite stronger regulations
06 Jan 2025 06:03 GMT
… trend. Companies such as Unilever, GlaxoSmithKline, among others, cited economic … to repatriate profits deter potential investors. “When investors are unsure about their … operating environment. Without these, investors will continue to prioritize safety …
-
Antibiotic Resistance Therapeutics Market Research Report 2025-2029: Key Insights by Pathogen and Therapy Type with Situation Analysis, Executive, and Investor Guides - ResearchAndMarkets.com
31 Dec 2024 13:59 GMT
… , with Situation Analysis, Executive, and Investor Guides" report has been …
6.91 Allergan
6.92 GlaxoSmithKline
6.93 Novartis
6.94 …
-
Pharma stocks: Divi’s Lab (+0.82%), IPCA (+0.83%) rise; Biocon (-1.86%), Glaxo (-1.44%) decline
12 Dec 2024 07:03 GMT
… , trading at ₹5,443.55.
GlaxoSmithKline: Dropped 1.44% to ₹2 … sector’s mixed performance reflects investor cautiousness, with Divi’s Lab … top gainers, while Biocon and Glaxo faced selling pressure.
Disclaimer: This …
-
Bacterial Vaccines Market CAGR of 8% size, share, growth & Forecast by 2024 To 2031 | GlaxoSmithKline plc, Pfizer Inc.
10 Dec 2024 14:45 GMT
… valuable information to professionals, stakeholders, investors, and newcomers seeking to understand … Players Highlighted in This Report:
• GlaxoSmithKline plc
• Pfizer Inc.
• Merck …
-
Stock to Watch Today: GlaxoSmithKline net profit rises 16% in Q2 FY24-25 on 5% revenue growth YoY
30 Oct 2024 02:31 GMT
GlaxoSmithKline (GSK) is likely to attract investor attention today after announcing its … gross and net profit margins. Investors may keep a close eye … does not constitute financial advice. Investors should perform due diligence before …
-
StockWatch: Moderna’s $1.1B R&D Cut, Profitability Delay Jolt Investors
16 Sep 2024 17:30 GMT
… a significant debate, and investors are unlikely to believe this … R&D forecasts: “Investors have heightened concerns on … imply GSK/PFE [GlaxoSmithKline and Pfizer] have locked up … which Fulcrum has licensed from GlaxoSmithKline (GSK) since 2019—did …
About
© 1995-2025